Literature DB >> 8345408

Participation of macrophages in segmental endocapillary proliferation preceding focal glomerular sclerosis.

T Saito1, T Ootaka, H Sato, T Furuta, T Sato, J Soma, K Abe, K Yoshinaga.   

Abstract

We studied infiltrating cells in the glomeruli of eight cases with focal segmental endocapillary proliferation (FSEP) using monoclonal antibodies to leukocyte common antigen, T cells, B cells, and monocytes/macrophages (Mo/M psi). It was demonstrated by sequential biopsies performed in five cases that FSEP preceded focal glomerular sclerosis (FGS). Cell types in FSEP were compared with those in FGS from 17 patients with persistent nephrotic syndrome, ten non-nephrotic patients, and eight patients with nephrotic syndrome which was initially responsive to steroid therapy but relapsed, as well as minimal change specimens from nine nephrotic patients. In the glomeruli, the mean total leukocyte counts increased significantly in the FSEP group (P < 0.01). The serial sections in FSEP revealed that Mo/M psi were the predominant cells and were localized in areas of endocapillary proliferation. T-cell or B-cell infiltration was less marked. The extensive intracapillary distribution of p150,95 antigen belonging to the integrin family and acting as a C3bi receptor suggested that FSEP may be mediated by adhesion molecules expressed on Mo/M psi. These findings indicate that Mo/M psi may play a key role in FGS which shows endocapillary proliferation in the initial stage.

Entities:  

Mesh:

Year:  1993        PMID: 8345408     DOI: 10.1002/path.1711700214

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  9 in total

Review 1.  Pathology of glomerular lipidosis.

Authors:  Hiroshi Sato; Nobuyuki Takahashi; Emiko Sato; Kiyomi Kisu; Sadayoshi Ito; Takao Saito
Journal:  Clin Exp Nephrol       Date:  2013-10-16       Impact factor: 2.801

2.  Elevated macrophage migration inhibitory factor (MIF) levels in the urine of patients with focal glomerular sclerosis.

Authors:  K Matsumoto; N Maruyama; T Maruyama; Y Ohnishi; S Nonaka; A Inoshita; K Ito; S Kitajima; M Abe; A Satomura; T Fujita
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

3.  Gastric pathology in patients with common variable immunodeficiency.

Authors:  A Zullo; A Romiti; V Rinaldi; A Vecchione; S Tomao; F Aiuti; L Frati; G Luzi
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

Review 4.  Systemic and renal lipids in kidney disease development and progression.

Authors:  Patricia Wahl; Gloria Michelle Ducasa; Alessia Fornoni
Journal:  Am J Physiol Renal Physiol       Date:  2015-12-23

5.  Podocyte injury-driven lipid peroxidation accelerates the infiltration of glomerular foam cells in focal segmental glomerulosclerosis.

Authors:  Satoshi Hara; Namiko Kobayashi; Kazuo Sakamoto; Toshiharu Ueno; Shun Manabe; Yasutoshi Takashima; Juri Hamada; Ira Pastan; Akiyoshi Fukamizu; Taiji Matsusaka; Michio Nagata
Journal:  Am J Pathol       Date:  2015-06-11       Impact factor: 4.307

6.  Glomerular Lipidosis in Dogs.

Authors:  Rebecca A Kohnken; Hayley Amerman; Cathy A Brown; Eva Furrow; George E Lees; Rachel E Cianciolo
Journal:  Vet Pathol       Date:  2017-06-05       Impact factor: 2.221

Review 7.  Dendritic cells and macrophages in kidney disease.

Authors:  Koichi Matsumoto; Noboru Fukuda; Masanori Abe; Takayuki Fujita
Journal:  Clin Exp Nephrol       Date:  2009-08-18       Impact factor: 2.801

8.  Participation of CR1 (CD35), CR3 (CD11b/CD18) and CR4 (CD11c/CD18) in membranoproliferative glomerulonephritis type I.

Authors:  J Soma; T Saito; J Seino; H Sato; T Ootaka; A Yusa; K Abe
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

9.  Focal segmental glomerulosclerosis with heterozygous apolipoprotein E5 (Glu3Lys).

Authors:  Masaru Sasaki; Tetsuhiko Yasuno; Kenji Ito; Akira Matsunaga; Satoshi Hisano; Yasuhiro Abe; Katsuhisa Miyake; Kosuke Masutani; Hitoshi Nakashima; Takao Saito
Journal:  CEN Case Rep       Date:  2018-05-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.